This site is intended for UK healthcare professionals

 
This promotional video has been developed, organised and funded by Novartis Pharmaceuticals UK Ltd. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast. Editorial support for this video has been provided by OmniaMed Communications.
Click here to access ENTRESTO® (sacubitril/valsartan) prescribing information (externally hosted). Adverse event reporting can be found at the bottom of this page.
ENTRESTO® (sacubitril/valsartan) is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
novartis-logo-transparent
Entresto
1:10

Heart Failure Foundation Course: Chronic heart failure with reduced ejection fraction: Burden, symptoms and diagnosis

2 October 2025

Sponsored

1:10
Maggie Simpson (Registered Nurse, NHS Scotland) introduces the first session of the Heart Failure Foundation Course 2025. This session explores the burden and symptoms of chronic heart failure with reduced ejection fraction, as well as the key steps involved in diagnosing the condition.

Watch the full on-demand video and the other videos in this series on the Heart Failure Foundation Course 2025 resource site.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email [email protected] or call 01276 698370.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

BJC TV

To continue, please confirm that you are a UK healthcare professional.